Dyslipidaemia

Role of Genetic Testing in Management of Dyslipidemia

Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?

Statin/ezetimibe SPC for better adherence to LLT

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Overview of adherence data with LLT highlighting the most recent data with PCSK9i

Metabolic Risk Factors and Effect of Alirocumab on CV Events

Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

Lipid management in patients with ACS/ASCVD

Improving Lipid Management for Patients Post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Atherosclerosis: Identifying risks and improving outcomes

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Act Now for Your ACS Patients: Summary

Act Now for Your ACS Patients: Patient Identification

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

What do us physicians and patients think about LLTs and goals of treatment?

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Public health recommendations for Lp(a) measurement

Single-Pill Combinations in Dyslipidemia

This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).

The European experience: Swedeheart and AIFA registries

Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.

Statin/Ezetimibe Combination VS Statin Monotherapy

Use of Lipid-Lowering Therapies Over 2 Years

APSC Consensus Recommendations on Dyslipidemia

ESC Lp(a) in Clinical practice EAS Consensus statement

CV Risk management in T1DM using guidelines

Event rates and Risk Factors for Recurrent CV Events

Evaluation of lipid management following ACS

Importance of lipid registries in cardiovascular prevention

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Approach for Patients with CAD: Focus on LDL-C Control

Lipid Management in Patients with Diabetes Mellitus

Relationship Between LDL-C LLTs and Risk of Stroke

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Cardiovascular Disease

PCSK9i after hospital discharge for acute MI

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

LLTs and Antithrombotic Therapy in PAD

LLTs Exposure Time and Major Vascular Risk Reduction

Possible Challenges Post One Year of ESC/EAS Guidelines

Prognostic impact of achieving LDL cholesterol guidelines

Perceptions and Barriers on the use of PCSK9 inhibitors

LDL-C The Only Causal Risk Factor for ASCVD

Why low-density lipoprotein-cholesterol, the only causal risk factor for atherosclerotic cardiovascular disease, is still overlooked and underestimated.

LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia

PCSK9 Inhibitors in Real World Practice